Budoucnost asistivních technologií v medicíně

doc. Ing. Lenka Lhotská, CSc.

Interní Med. 2018; 20(4): 163  

Latest developments in the management of resistant hypertension

prof. MUDr. Renata Cífková, CSc.

Interní Med. 2018; 20(4): 167-170 | DOI: 10.36290/int.2018.030  

Hypertension resistant to treatment is currently defined as a situation when the recommended treatment strategy fails to loweroffice blood pressure to values < 140/90 mmHg, and inadequate control of blood pressure is confirmed by ambulatory bloodpressure monitoring or home blood pressure measurement. The recommended treatment strategy should include treatmentwith optimal or best-tolerated doses of three or more drugs that should include a diuretic and, typically, an ACE inhibitor orangiotensin receptor blocker and a calcium-channel blocker. The estimated prevalence using the above definition is likely to be< 10% of treated patients. Pseudoresistant...

Why do we fail when treating dyslipidemia?

MUDr. Tereza Altschmiedová, prof. MUDr. Michal Vrablík, Ph.D.

Interní Med. 2018; 20(4): 171-176 | DOI: 10.36290/int.2018.031  

Dyslipidemia represents a risk factor in many diseases, of which atherosclerosis is considered to be the most serious cause of thelater development of cardiovascular disease, which is still the most significant cause of death worldwide. At present, almost nobodydisputes the treatment of dyslipidemias as an effective means of preventing cardiovascular disease. Its basis in all patientsis non-pharmacological, with the drug of first choice being statins, for the benefits and the safety of which we have long-termevidence. However, in order that the treatment of dyslipidemias achieves its goal of decreasing cardiovascular morbidity andmortality, it is necessary...

Practical comments on fat consumption with relation to atherosclerosis and cardiovascular events

MUDr. Igor Romanko, doc. MUDr. Michal Vrablík, Ph.D., MUDr. Michaela Romanko Ingrischová

Interní Med. 2018; 20(4): 178-182 | DOI: 10.36290/int.2018.032  

Changes of dietary habits are cornerstone of lifestyle interventions in prevention of cardiovascular diseases at all levels. Guidelinesof expert-societies offer basic recommendations about daily diet. These could be too broad for patients, who might experiencetrouble in finding the right way on contemporary multivariate food market. It is vital for patients to know not only what is goodfor health, but why is it so as well. In this article we focus on fats, as one of basic nutrients, and attempt to show their importancefor healthy diet and prevention of cardiovascular diseases, so it would be comprehensible for physicians and patients.

Prediabetes

prof. MUDr. Kateřina Štechová, Ph.D.

Interní Med. 2018; 20(4): 183-188 | DOI: 10.36290/int.2018.033  

Prediabetes (impaired glucose homeostasis) is clinically silent period preceding overt diabetes. Increased fasting glycaemia and/or higher glycaemia after glucose load are observed but glycaemia values do not reach the threshold diagnostic for diabetes.Currently prediabetes is not considered to be a specific clinical entity (disease) despite the evidence documenting that “toxic cardio-metabolic” processes during prediabetes are harmful and may for instance initiate the development of chronic microvascularcomplications. In prediabetes pathogenesis the development of insulin resistance is crucial. First step towards the development ofinsulin...

How to examine and support microcirculation in pactients with diabetic foot

MUDr. Pavlína Piťhová, Ph.D.

Interní Med. 2018; 20(4): 189-196 | DOI: 10.36290/int.2018.058  

Diabetic foot syndrome is a debilitating diabetic complication. The treatment must be complex, containing offloading of theaffected foot, revascularization procedures in presence of ischemia, antibiotic treatment if infection is present, debridement andproper wound bed preparation and optimal wound care choice. It seems that the most important role in healing process playsfunctional microcirculation. In support of microcirculation we can use non-pharmacological (hyperbaric oxygenotherapy, localphysical treatments) and pharmacological methods as alprostadile or sulodexide.

Obesity treatment and experience with a centrally-acting antiobesity agent?

MUDr. Dita Pichlerová

Interní Med. 2018; 20(4): 198-200 | DOI: 10.36290/int.2018.059  

The article briefly summarizes the development of antiobesity drugs from the beginning of use to the present and introduces anovel dual-combination agent with central dual action. A noninterventional, observational, multidisciplinary trial of the use ofthe new drug will be presented in two parts. In this issue, we deal with its three-month efficacy, and the next one will present asummary of six-month administration including adverse effects and some patient opinions of the novel therapy.

New European and Czech guidelines for hepatitis B therapy

prof. MUDr. Petr Husa, CSc.

Interní Med. 2018; 20(4): 202-206 | DOI: 10.36290/int.2018.034  

Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors predominantlyvaccination policy and migration. Chronic hepatitis B means the duration of HBV infection for more than 6 months.It is a dynamic process reflecting the interaction between HBV replication and the host immune response and not all patientswith chronic HBV infection have chronic hepatitis B. All patients with chronic HBV infection are in increased risk of progression toliver cirrhosis and hepatocellular carcinoma. The long-term administration of potent nucleos(t)ide analogue with high barrier ofresistance (tenofovir,...

Edoxaban

prof. MUDr. Lenka Špinarová, Ph.D., prof. MUDr. Jindřich Špinar, CSc., doc. MUDr. Růžena Lábrová, Ph.D.

Interní Med. 2018; 20(4): 207-210 | DOI: 10.36290/int.2018.035  

Blocade of factor Xa becomes a routine part of clinical praxis instead of coumarine blockade with warfarin, providing a morebenfitial and safer effect. The main indiactions are nonvalvular atrial fibrillation, deep venous trombosis, lung embolism and inrecent time also electric cardioversion. Edoxaban appears as the fourth drug which has also evidence based data from clinicaltrials. Its advantage is also a once daily dosage.

Co nového přinesl kongres ESC 2018 o apixabanu?

prof. MUDr. Josef Kautzner, CSc., FESC

Interní Med. 2018; 20(4): 211-214  

Selected news from the current guidelines for treating chronic venous disease issued in June 2018

doc. MUDr. Debora Karetová, CSc.

Interní Med. 2018; 20(4): 215-218  

New guidelines for diagnosing and treating chronic venous diseases have recently been published in the International Angiologyjournal which is the official journal of the International Union of Angiology (IUA). The document was created under the supervisionof several international societies, i.e. not only the IUA, but also involved were the European Venous Forum, the CardiovascularDisease Educational and Research Trust, and Union Internationale de Phlebologie. The main editor of these guidelines is AndrewNicolaides. Altogehter, they were prepared and developed by more than 40 renowned authors. Very comprehensive is the chapteron the pathophysiology...

Zemřel prof. MUDr. Jaroslav Rybka, DrSc.

MUDr. Eva Račická

Interní Med. 2018; 20(4): 210